Board of Directors

Brendan P O’Grady Chief Executive Officer of Assertio Holdings

Mr. O’Grady, age 57, most recently served as CEO of the Global Formulations Business at Glenmark Pharmaceuticals Ltd. (India: NSE), a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O’Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell (NYSE: AMWL), an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), from 2001 to 2021, most recently serving as CEO and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva’s North America business, including specially, generic and over-the-counter pharmaceuticals, and the abbreviated new drug application drug distribution business. Prior to that, Mr. O’Grady served in various positions of increasing responsibility at Sanofi (Nasdaq: SNY) from 1991 to 2001. Mr. O’Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York and an M.B.A. from Baker University

Sravan Emany Chief Financial Officer, Ironwood Pharmaceuticals

Mr. Emany has served as a director of Assertio since November 2023. Since December 2021, Mr. Emany has served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, a Nasdaq listed healthcare company. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.

Heather Mason Former Senior Executive of Abbott Laboratories

Ms. Mason has served as a director of Assertio since February 2019. Ms. Mason is a former senior executive of Abbott Laboratories, having recently retired as executive vice president (EVP) of Abbott Nutrition. Ms. Mason also served as EVP, global commercial Operations at Abbott and senior vice president of Abbott Diabetes Care. Ms. Mason joined Abbott in 1990 and held positions in Abbott’s U.S. pharmaceutical business, including oversight of Abbott’s specialty pharmaceuticals, its diabetes/metabolics and oncology franchises, and managed health care. Ms. Mason also served as vice president (VP), international marketing, and VP, Latin American operations, in Abbott’s international pharmaceutical business. Prior to joining Abbott, Ms. Mason worked for Quaker Oats, FMC Corporation, and Commonwealth Edison. Ms. Mason holds a B.S.E. in Industrial Engineering from the University of Michigan and a M.B.A. from the University of Chicago.

Jeffrey Vacirca CEO and Chairman of the Board of New York Cancer & Blood Specialists

Jeffrey Vacirca, MD, FACP, is a renowned cancer physician and visionary leader with extensive experience and commitment to community oncology. Dr. Vacirca assumed the role of CEO and Chairman of the Board of New York Cancer & Blood Specialists (NYCBS) in 2008. After two years, the practice emerged as a stronger unified group of physicians dedicated to reinventing themselves as the premier cancer care deliverers of New York.

Dr. Vacirca takes action against key billings, including abuse of pharmacy benefit managers (PBMs) and sequester cuts. He formed the Conquering Cancer PAC, which advocates for cancer patients and strives to ensure access and availability for all patients no matter where they live.

He also serves on the board of directors of Annexus Health, OneOncology, and the American Red Cross of Greater New York. Most of his roles in these remarkable companies focus on legislative advocacy for the cost of cancer care and access. Dr. Vacirca is the immediate past president of the Community Oncology Alliance (COA) and continues to be a member of their executive committee. He serves on the board of Scientific Advisory for Caris Life Sciences, and is president and co-founder of the National Translational Research Group. He has also been part of early funding for remarkable companies, including Cedar, Thyme Care, and Sherpa Health. Dr. Vacirca co-founded Odonate Therapeutics in 2016.

Dr. Vacirca is the founder and Chairman of the Board of Directors of the New York Cancer Foundation, which provides financial assistance to patients undergoing treatment for cancer. In addition, Dr. Vacirca is the Medical Director of Oncology Network Development at Mount Sinai Health Network and Lab Director for the Long Island Association for AIDS Care (LIAAC).

Dr. Vacirca was honored as Humanitarian of the Year by the American Red Cross and received its Corporate Leadership Award on behalf of NYCBS. He was awarded the Red Door Award for Leadership and Cancer Advocacy by the Red Door Community and received the Founders Medalist by The Brooklyn Hospital. Dr. Vacirca also received the Theodore Roosevelt Award for outstanding dedication to patient care and was named Newsday’s Top Doctor. He was also honored for his role in enabling the Long Island Association for AIDS Care staff to bring state-of-the-art HIV testing to New York.

Peter D. Staple Chairman of the Board of Directors

Mr. Staple has served as a director of Assertio since November 2003. Since March 2008, Mr. Staple has served as chief executive officer (CEO) and director of Corium International, Inc., a publicly held biopharmaceutical company. From 2002 to March 2008 he served as director, and from 2002 to November 2007 as chief executive officer of BioSeek, Inc., a privately held drug discovery company. From 1994 to 2002, Mr. Staple was a member of the senior executive team at ALZA Corporation, where he was most recently executive vice president, chief administrative officer and general counsel. Prior to joining ALZA, Mr. Staple held the position of vice president, associate general counsel for biopharmaceutical company Chiron Corporation. Mr. Staple previously served as vice president, associate general counsel for Cetus Corporation, a biotechnology company. Mr. Staple received a J.D. degree from Stanford Law School and a B.A. degree from Stanford University.

Sigurd C. Kirk Former Executive Vice President, Allergan plc.

Mr. Kirk has served as a director of Assertio since April 2024. Mr. Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products. Since 2021, Mr. Kirk has served as a consultant and director to privately-held pharmaceutical companies and, from May 2021 to January 2024, served as a director and member of the audit committee of Aravive, Inc., a development stage oncology company. From 2009 until its acquisition by AbbVie Inc. in May 2020, Mr. Kirk held various positions at Allergan plc. (formerly Actavis), a pharmaceutical company. From May 2012 until May 2020, Mr. Kirk was Executive Vice President, Corporate Business Development at Allergan plc., where he was a member of the Executive Leadership Team. He was an integral member assessing development and commercial opportunities, leading due diligence, as well as negotiating and transacting key legal and financial terms. Mr. Kirk also served as Senior Vice President, Global Controller and Chief Accounting Officer for Barr Pharmaceuticals, Inc. from 2007 until 2009, after having served in positions of increasing responsibility at Barr from 2003. Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification. Mr. Kirk received his Bachelor of Business Administration degree from Pace University.

William T. McKee Former Chief Financial Officer, Barr Pharmaceuticals

Mr. McKee has served as director of Assertio since March 2017. He served as chief operating officer and chief financial officer (CFO) at EKR Therapeutics, Inc., a privately held specialty pharmaceutical company from 2010 until EKR was sold to Cornerstone Therapeutics Inc. in 2012. Until March 2010, Mr. McKee served as the executive vice president and CFO of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited, a generic pharmaceutical company, and the successor entity to Barr Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, which was acquired by Teva. Mr. McKee was also executive vice president and CFO of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr until its acquisition. Prior to joining Barr, Mr. McKee served as director of International Operations and vice president of finance at Absolute Entertainment, Inc., a private developer and marketer of entertainment software. Mr. McKee previously worked at Gramkow & Carnevale, CPAs and Deloitte & Touche. Mr. McKee serves on the boards of Agile Therapeutics, Inc., a publicly held specialty biopharmaceutical company, Cerulean, Inc., a publicly held clinical-stage, oncology-focused company and Synthetic Genomics Inc., a privately held synthetic biology company. Mr. McKee received a B.A. in business from the University of Notre Dame.